Long-term safety study of LUM-201 for growth hormone deficiency
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Hormones & metabolism clinical trials.
This trial is for children who have already completed one year of treatment with LUM-201 in an earlier study. It continues to test the medicine's safety over a longer period, so children can keep receiving treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have completed 12 months in the earlier LUM-201 growth hormone study.
- You are eligible to continue treatment as decided by the study doctor.
- If you are sexually active, you must use birth control.
- You are not pregnant.
- You are not taking certain medications that could interfere with LUM-201 (the study doctor will check).
- You do not have a medical condition that makes LUM-201 unsafe, in the doctor's opinion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called LUM-201 for children who haven't grown enough because their bodies don't make enough growth hormone. It aims to help kids who haven't been treated before and are still at an early stage of puberty.
This trial tests a new growth hormone medicine (GB06) for children whose bodies don't make enough growth hormone naturally. The study will see if this treatment helps children grow taller over time.
This study tests a new growth hormone injection (GB08) for children who are not growing well because of a condition called growth hormone deficiency. It aims to see if the medicine is safe and helps them grow taller.
This trial checks the long-term safety of LUM-201 in children who have idiopathic growth hormone deficiency and already completed an earlier LUM-201 study. If you previously took LUM-201 and are allowed to continue, the study may help your care team monitor ongoing effects over time.
This study tracks the safety of lonapegsomatropin in children being treated for growth hormone deficiency (GHD). It’s meant to check for side effects and make sure the medicine continues to be safe in real-world use.
This trial tests an oral medication called GS3-007a for children who have not yet reached puberty and have growth hormone deficiency. The goal is to see if it helps them grow taller.
Hear when a new Growth Hormone Deficiency (GHD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.